The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
|Articles|September 12, 2016
Recap of the 5 Roads Out of Retail Pharmacy
Erin L. Albert, MBA, PharmD, JD, weaves together the full recap of all 5 parts of the series with special questions from our valued listeners directed at our series participants.
Advertisement
Erin L. Albert, MBA, PharmD, JD,
weaves together the full recap of all 5 parts of the series with special questions from our valued listeners directed at our series participants:
- Peter Dunn, Pete the Planner
- Hazel Walker, Master of Networking
- Anthony Guerra, PharmD, host of "Pharmacy Future Leaders" podcast segment.
Advertisement
Related to this article
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
5